Skip to main content
Premium Trial:

Request an Annual Quote

Max Planck Partners with Evotec Technologies and Definiens to Develop High Throughput RNAi and Imaging Platform

NEW YORK, Sept. 19 (GenomeWeb News) - The Max Planck Institute of Molecular Cell Biology and Genetics in Dresden, Germany announced today that it is teaming up with German companies Evotec Technologies of Hamburg and Definiens of Munich to develop a new platform for high throughput RNAi and cell-based screening and image analysis.

 

The partnership is part of "biosaxony," a Saxon biotech initiative endorsed by the state government of Saxony, Germany.

 

MPI-CBG was the first institute to publish a genome-scale analysis using RNAi in C. elegans, and will now provide the assays, location and laboratory facilities for the study. The Institute will use Evotec's confocal optics-based fluorescent imaging platform Opera to collect data and Definiens' object-oriented image analysis platform called Cognition Network Technology to analyze the data.

 

The group hopes to commercialize the methods they develop for industry use.

 

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.